Overview

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

Status:
Completed

Trial end date:
2018-04-23

Target enrollment:

Participant gender:

Summary

This study will be conducted to assess the effect of mild and moderate hepatic impairment on the pharmacokinetics (PK) of lemborexant after a single-dose administration.

Phase:

Phase 1

Details

Lead Sponsor:

Eisai Inc.

Collaborator:

Purdue Pharma LP

Treatments:

Lemborexant